Data from: Nasal Glucagon Reverses Insulin-induced Hypoglycemia With Less Rebound Hyperglycemia: Pooled Analysis of Clinical Trials
Published: 28 February 2024| Version 1 | DOI: 10.17632/4jgfwnkzb4.1
Contributors:
Elizabeth Seaquist, Marga Giménez, Yu Yan, Munehide Matsuhisa, Christi Kao, R. Paul Wadwa, Yukiko Nagai, Kamlesh KhuntiDescription
Supplementary data for the analysis of treatment success (defined as an increase in blood glucose to ≥70 mg/dL or an increase of ≥20 mg/dL from nadir within 15 or 30 minutes after receiving glucagon) based on Ademolus Classification of Hypoglycemia. Data are from the manuscript titled "Nasal Glucagon Reverses Insulin-induced Hypoglycemia With Less Rebound Hyperglycemia: Pooled Analysis of Clinical Trials". The article is accepted for publication by Journal of the Endocrine Society, and the supplementary data were peer reviewed by the journal as part of the review process.
Files
Categories
Diabetes, Hypoglycemia
Funding
Eli Lilly and Company